Rossella Manfredini

List of Publications by Year
in descending order

130 papers	4,199 citations	136950 32 h-index	123424 61 g-index
131 all docs	131 docs citations	131 times ranked	5507 citing authors

#	Article	IF	Citations
1	Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework. Diagnosis, 2022, 9, 115-122.	1.9	3
2	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	5.1	6
3	BTK Inhibitors Impair Platelet-Mediated Antifungal Activity. Cells, 2022, 11, 1003.	4.1	7
4	The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 5242.	4.1	7
5	SOX2 Is a Univocal Marker for Human Oral Mucosa Epithelium Useful in Post-COMET Patient Characterization. International Journal of Molecular Sciences, 2022, 23, 5785.	4.1	3
6	Characterization of New ATM Deletion Associated with Hereditary Breast Cancer. Genes, 2021, 12, 136.	2.4	7
7	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	4.1	19
8	Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis. Npj Precision Oncology, 2021, 5, 4.	5.4	10
9	iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification. Genes, 2021, 12, 384.	2.4	21
10	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
11	Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, <i>CALR</i>-mutated MPNs. Blood Advances, 2021, 5, 2184-2195.	5.2	12
12	Monocyte Distribution Width (MDW) as novel inflammatory marker with prognostic significance in COVID-19 patients. Scientific Reports, 2021, 11, 12716.	3.3	38
13	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 9159.	4.1	7
14	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	3.7	9
15	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 2021, 13, 4582.	3.7	28
16	Pre-existing cytopenia heralding de novo acute myeloid leukemia: uncommon presentation of NPM1-mutated AML in a single-center study. Leukemia Research, 2021, 111, 106747.	0.8	0
17	Single Cell Mutation Analysis Delineates Clonal Architecture in Leukemic Transformation of Myeloproliferative Neoplasms. Blood, 2021, 138, 56-56.	1.4	1
18	Magnesium favors the capacity of vitamin D3 to induce the monocyte differentiation of U937 cells. Magnesium Research, 2021, 34, 114-129.	0.5	1

#	Article	IF	Citations
19	Preclinical study for treatment of hypospadias by advanced therapy medicinal products. World Journal of Urology, 2020, 38, 2115-2122.	2.2	11
20	Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol. International Journal of Molecular Sciences, 2020, 21, 7366.	4.1	6
21	Wnt/CTNNB1 Signal Transduction Pathway Inhibits the Expression of ZFP36 in Squamous Cell Carcinoma, by Inducing Transcriptional Repressors SNAI1, SLUG and TWIST. International Journal of Molecular Sciences, 2020, 21, 5692.	4.1	6
22	Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants. Scientific Reports, 2019, 9, 10558.	3.3	31
23	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	1.4	12
24	miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nature Communications, 2019, 10, 5697.	12.8	48
25	Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation. Stem Cells and Development, 2018, 27, 225-236.	2.1	17
26	Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients. Leukemia, 2018, 32, 438-449.	7.2	26
27	Role of TGF â€Î²1/miRâ€382â€5p/ SOD 2 axis in the induction of oxidative stress in CD 34+ cells from primary myelofibrosis. Molecular Oncology, 2018, 12, 2102-2123.	4.6	19
28	Bone marrowâ€“specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood, 2018, 132, 2053-2066.	1.4	20
29	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. Frontiers in Pharmacology, 2018, 9, 196.	3.5	15
30	Calreticulin Ins5 and Del52 Mutations Impair Unfolded Protein and Oxidative Stress Responses in Hematopoietic Cells. Blood, 2018, 132, 4332-4332.	1.4	1
31	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget, 2018, 9, 21758-21769.	1.8	3
32	Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms. Blood, 2018, 132, 1777-1777.	1.4	0
33	Absence of Calreticulin Phenocopies Cellular Abnormalities Induced By Calreticulin Exon-9 Mutation in Myeloproliferative Neoplasms. Blood, 2018, 132, 1780-1780.	1.4	0
34	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy, 2017, 19, 1447-1461.	0.7	7
35	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	6.2	27
36	Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis. International Journal of Molecular Sciences, 2017, 18, 145.	4.1	14

#	Article	IF	Citations
37	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. Molecular Medicine, 2017, 23, 235-246.	4.4	9
38	miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. Oncotarget, 2017, 8, 21380-21397.	1.8	13
39	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	1.8	49
40	Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing. BioMed Research International, 2016, 2016, 1-14.	1.9	47
41	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	6.2	16
42	Genomic landscape of megakaryopoiesis and platelet function defects. Blood, 2016, 127, 1249-1259.	1.4	53
43	miR-382-5p Controls Hematopoietic Stem Cell Differentiation Through the Downregulation of MXD1. Stem Cells and Development, 2016, 25, 1433-1443.	2.1	31
44	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
45	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	5.1	6
46	Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFÎºB. Blood, 2016, 128, 1203-1203.	1.4	1
47	The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells. Oncotarget, 2016, 7, 45429-45443.	1.8	12
48	MAF Induces Inflammatory Mediators Involved in the Pathogenesis of Primary Myelofibrosis. Blood, 2016, 128, 3132-3132.	1.4	0
49	MiR-494-3p Overexpression Leads to SOCS6 Downregulation and Supports Megakaryocytopoiesis in Primary Myelofibrosis CD34+ Hematopoietic Stem/Progenitor Cells. Blood, 2016, 128, 4272-4272.	1.4	0
50	Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa. British Journal of Dermatology, 2015, 173, 731-738.	1.5	29
51	MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF. Cell Death and Differentiation, 2015, 22, 1906-1921.	11.2	60
52	Abnormal expression patterns of<i>WT1-as, MEG3</i>and<i>ANRIL</i>long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. Leukemia and Lymphoma, 2015, 56, 492-496.	1.3	14
53	Integrative Analysis of Copy Number and Gene Expression Data Suggests Novel Pathogenetic Mechanisms in Primary Myelofibrosis. Blood, 2015, 126, 2830-2830.	1.4	0
54	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	1.4	115

#	Article	IF	Citations
55	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	7.2	66
56	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
57	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia, 2014, 28, 1811-1818.	7.2	75
58	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	1.4	105
59	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. Blood, 2014, 124, 405-405.	1.4	47
60	C-Myb Restrains Megakaryopoiesis through the Hsa-MiR-486-3p-Driven Down-Regulation of C-Maf. Blood, 2014, 124, 5124-5124.	1.4	0
61	Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study. Blood, 2014, 124, 1867-1867.	1.4	0
62	Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. Stem Cells and Development, 2013, 22, 1097-1111.	2.1	95
63	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
64	Co-Culture of Hematopoietic Stem/Progenitor Cells with Human Osteblasts Favours Mono/Macrophage Differentiation at the Expense of the Erythroid Lineage. PLoS ONE, 2013, 8, e53496.	2.5	16
65	Impact Of Prognostically Detrimental Mutations (ASXL1, EZH2, SRSF2, IDH1/2) On Outcomes In Patients With Myelofibrosis Treated With Ruxolitinib In COMFORT-II. Blood, 2013, 122, 107-107.	1.4	2
66	Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis. Blood, 2013, 122, 1600-1600.	1.4	0
67	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	1.4	0
68	Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.	1.4	0
69	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood, 2012, 119, 217-226.	1.4	52
70	Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression. Experimental Hematology, 2012, 40, 1043-1054.e6.	0.4	13
71	Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F-mutated SET2 cells. Blood, 2012, 119, e120-e130.	1.4	34
72	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	1.4	0

#	Article	IF	Citations
73	Regulatory Mrna/Microrna Networks in CD34+ Cells From Primary Myelofibrosis.. Blood, 2012, 120, 2854-2854.	1.4	0
74	Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Experimental Hematology, 2011, 39, 360-374.e5.	0.4	73
75	Treatment with Ruxolitinib (INCB018424) Induced Changes of Microrna Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia,. Blood, 2011, 118, 3852-3852.	1.4	1
76	C-Myb Transactivates the Expression of Erythroid Hsa-miR16-2 Gene,. Blood, 2011, 118, 3386-3386.	1.4	0
77	c-myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression. Blood, 2010, 116, e99-e110.	1.4	95
78	Bone Marrow-Derived Hematopoietic Cells Undergo Myogenic Differentiation Following a Pax-7 Independent Pathway. Stem Cells, 2010, 28, 965-973.	3.2	22
79	Purinergic Stimulation of Human Bone Marrow-Derived Mesenchymal Stem Cells Modulate Their Function and Differentiation Potential.. Blood, 2010, 116, 3848-3848.	1.4	0
80	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. Experimental Hematology, 2009, 37, 1176-1185.e21.	0.4	17
81	Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. Leukemia, 2009, 23, 997-1000.	7.2	22
82	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â˜ cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	1.4	62
83	Purinergic Signaling Differentially Modulates Normal and Leukemic Hematopoiesis.. Blood, 2009, 114, 1436-1436.	1.4	0
84	Purinergic Signaling Modulates Human Bone Marrow-Derived Mesenchymal Stem Cells Function.. Blood, 2009, 114, 1441-1441.	1.4	1
85	Deranged MicroRNA 16-2 Expression Contributes to Erythropoiesis in Polycythemia Vera.. Blood, 2009, 114, 3896-3896.	1.4	0
86	Role of CD34 Antigen in Myeloid Differentiation of Human Hematopoietic Progenitor Cells. Stem Cells, 2008, 26, 950-959.	3.2	30
87	Isolation and characterization of a murine resident liver stem cell. Cell Death and Differentiation, 2008, 15, 123-133.	11.2	29
88	Dysregulated Expression of MicroRNA-16 Contributes to Abnormal Erythropoiesis in Patients with Polycythemia Vera. Blood, 2008, 112, 179-179.	1.4	2
89	Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34â˜ cell Population with Intrinsic Resistance to IMATINIB Treatment. Blood, 2008, 112, 4221-4221.	1.4	0
90	Eosinophils, but not neutrophils, exhibit an efficient DNA repair machinery and high nucleolar activity. Haematologica, 2007, 92, 1311-1318.	3.5	18

#	Article	IF	Citations
91	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood, 2007, 109, 533-542.	1.4	93
92	Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma. British Journal of Dermatology, 2007, 156, 62-71.	1.5	14
93	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.4	71
94	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	3.2	111
95	Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108, 218-227.	1.4	226
96	Virally mediated MafB transduction induces the monocyte commitment of human CD34+ hematopoietic stem/progenitor cells. Cell Death and Differentiation, 2006, 13, 1686-1696.	11.2	67
97	Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia. Leukemia, 2006, 20, 1751-1758.	7.2	38
98	The Kinetic Status of Hematopoietic Stem Cell Subpopulations Underlies a Differential Expression of Genes Involved in Self-Renewal, Commitment, and Engraftment. Stem Cells, 2005, 23, 496-506.	3.2	45
99	Correlation between differentiation plasticity and mRNA expression profiling of CD34+-derived CD14â^' and CD14+ human normal myeloid precursors. Cell Death and Differentiation, 2005, 12, 1588-1600.	11.2	22
100	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. Blood, 2005, 106, 1730-1730.	1.4	0
101	Requirement of the coiled-coil domains of p92c-Fes for nuclear localization in myeloid cells upon induction of differentiation. Oncogene, 2003, 22, 1712-1723.	5.9	12
102	Development of an IL-6 antagonist peptide that induces apoptosis in 7TD1 cells. Peptides, 2003, 24, 1207-1220.	2.4	14
103	Gene expression profile of Vitamin D3 treated HL60 cells shows an incomplete molecular phenotypic conversion to monocytes. Cell Death and Differentiation, 2002, 9, 1185-1195.	11.2	12
104	Physiological levels of 1alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Journal of Leukocyte Biology, 2002, 71, 641-51.	3.3	31
105	A functionally active RARÎ± nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines. Cell Death and Differentiation, 2001, 8, 70-82.	11.2	6
106	Induction of a functional vitamin D receptor in all-trans-retinoic acid-induced monocytic differentiation of M2-type leukemic blast cells. Cancer Research, 1999, 59, 3803-11.	0.9	26
107	Antisense Inhibition of Bax mRNA Increases Survival of Terminally Differentiated HL60 Cells. Oligonucleotides, 1998, 8, 341-350.	4.3	9
108	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	1.4	29

#	Article	IF	Citations
109	Presence of a functional vitamin D receptor does not correlate with vitamin D3 phenotypic effects in myeloid differentiation. Cell Death and Differentiation, 1997, 4, 497-505.	11.2	12
110	Antisense Inhibition of c-fes Proto-oncogene Blocks PMA-Induced Macrophage Differentiation in HL60 and in FDC-P1/MAC-11 Cells. Blood, 1997, 89, 135-145.	1.4	3
111	Antisense inhibition of c-fes proto-oncogene blocks PMA-induced macrophage differentiation in HL60 and in FDC-P1/MAC-11 cells. Blood, 1997, 89, 135-45.	1.4	13
112	Inhibition of cell growth by accumulated spermine is associated with a transient alteration of cell cycle progression. Life Sciences, 1996, 58, 2065-2072.	4.3	15
113	All-trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Experimental Hematology, 1995, 23, 117-25.	0.4	38
114	Role of c-fes protooncogene in myeloid differentiation. Cell Death and Differentiation, 1995, 2, 155-62.	11.2	2
115	Expression and Function of Nerve Growth Factor and Nerve Growth Factor Receptor on Cultured Keratinocytes. Journal of Investigative Dermatology, 1994, 103, 13-18.	0.7	165
116	Expression of B7 Costimulatory Molecule in Cultured Human Epidermal Langerhans Cells Is Regulated at the mRNA Level. Journal of Investigative Dermatology, 1994, 103, 54-59.	0.7	48
117	Antisense strategies in leukemia. Haematologica, 1994, 79, 107-11.	3.5	3
118	Expression and function of nerve growth factor and nerve growth factor receptors on cultured normal human keratinocytes. Journal of Dermatological Science, 1993, 6, 14.	1.9	0
119	Overexpression of C-kit in a Leukemic Cell Population Carrying a Trisomy 4 and its Relationship with the Proliferative Capacity. Leukemia and Lymphoma, 1993, 9, 495-501.	1.3	16
120	Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.. Journal of Experimental Medicine, 1993, 178, 381-389.	8.5	60
121	Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. European Journal of Haematology, 1993, 50, 141-148.	2.2	28
122	Antisense Strategies to Characterize the Role of Genes and Oncogenes Involved in Myeloid Differentiationa. Annals of the New York Academy of Sciences, 1992, 660, 11-26.	3.8	10
123	Terminal Differentiation. Annals of the New York Academy of Sciences, 1992, 663, 180-186.	3.8	6
124	Proliferation, Differentiation Arrest, and Survival in Leukemic Blast Cells. Annals of the New York Academy of Sciences, 1992, 663, 202-214.	3.8	6
125	Abundance of the primary transcript and its processed product of growth-related genes in normal and leukemic cells during proliferation and differentiation. Cancer Research, 1992, 52, 11-6.	0.9	99
126	Overexpression of the MPO gene occurring in a case of APL without unusual genotypic characteristics. Leukemia Research, 1990, 14, 735-742.	0.8	4

#	Article	IF	Citations
127	Noncoordinated expression of S6, S11, and S14 ribosomal protein genes in leukemic blast cells. Cancer Research, 1990, 50, 5825-8.	0.9	41
128	Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 1990, 1, 543-8.	0.8	8
129	Detection of low abundance mRNA of myeloid specific genes in cells of acute and chronic lymphoid leukemias by cRNA hybridization. Leukemia, 1990, 4, 688-93.	7.2	6
130	Ratios between the abundance of messenger RNA and the corresponding protein of two growth-related genes, c-myc and vimentin, in leukemia blast cells. Cancer Research, 1990, 50, 1988-91.	0.9	12